Clemastine
As of the edition of 20 October 2026, Clemastine is a small molecule: marketed, first approved in 1967 (CH); acts on HRH1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- TAVIST-1
- First approved
- 17 October 1967 (CH)
- Approvals on record
- 10 in 2 regions
- Holder of the most recent approval
- Novartis; 3 holders in all
- Registered trials
- 15, 2 stopped early
- Disease areas
- Immune system; Nervous system; Inherited and neonatal; Eye; Heart and blood vessels; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HRH1 | Histamine H1 receptor | P35367 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 2 | 0 | 0 |
| Phase 1 | 3 | 2 | 1 | 0 |
| Phase 2 | 6 | 1 | 5 | 0 |
| Phase 3 | 4 | 1 | 0 | 2 |
| All trials | 15 |